AP3535A - Fusion polypeptide against eb virus-induced tumor and colicin ia mutant - Google Patents

Fusion polypeptide against eb virus-induced tumor and colicin ia mutant

Info

Publication number
AP3535A
AP3535A AP2012006327A AP2012006327A AP3535A AP 3535 A AP3535 A AP 3535A AP 2012006327 A AP2012006327 A AP 2012006327A AP 2012006327 A AP2012006327 A AP 2012006327A AP 3535 A AP3535 A AP 3535A
Authority
AP
ARIPO
Prior art keywords
colicin
mutant
virus
fusion polypeptide
induced tumor
Prior art date
Application number
AP2012006327A
Other languages
English (en)
Other versions
AP2012006327A0 (en
Inventor
Xiaoqing Qiu
Original Assignee
Protein Design Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Lab Ltd filed Critical Protein Design Lab Ltd
Publication of AP2012006327A0 publication Critical patent/AP2012006327A0/xx
Application granted granted Critical
Publication of AP3535A publication Critical patent/AP3535A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AP2012006327A 2009-12-17 2010-02-26 Fusion polypeptide against eb virus-induced tumor and colicin ia mutant AP3535A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009102428380A CN102101888B (zh) 2009-12-17 2009-12-17 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法
PCT/CN2010/070762 WO2011072501A1 (zh) 2009-12-17 2010-02-26 抗EB病毒诱发的肿瘤的融合多肽和大肠菌素Ia突变体

Publications (2)

Publication Number Publication Date
AP2012006327A0 AP2012006327A0 (en) 2012-06-30
AP3535A true AP3535A (en) 2016-01-13

Family

ID=44154977

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006327A AP3535A (en) 2009-12-17 2010-02-26 Fusion polypeptide against eb virus-induced tumor and colicin ia mutant

Country Status (30)

Country Link
US (1) US8883161B2 (ko)
EP (1) EP2514768B1 (ko)
JP (1) JP5683603B2 (ko)
KR (1) KR101464842B1 (ko)
CN (1) CN102101888B (ko)
AP (1) AP3535A (ko)
AU (1) AU2010333588B2 (ko)
BR (1) BR112012017350A2 (ko)
CA (1) CA2784784C (ko)
CL (1) CL2012001609A1 (ko)
CO (1) CO6541633A2 (ko)
CR (1) CR20120329A (ko)
CU (1) CU20120096A7 (ko)
DK (1) DK2514768T3 (ko)
DO (1) DOP2012000164A (ko)
EA (1) EA030638B1 (ko)
ES (1) ES2634944T3 (ko)
GE (1) GEP20156228B (ko)
HK (1) HK1159123A1 (ko)
HU (1) HUE033298T2 (ko)
IL (1) IL220296A (ko)
MA (1) MA33921B1 (ko)
MX (1) MX2012006952A (ko)
NZ (1) NZ600729A (ko)
PE (1) PE20121722A1 (ko)
SG (1) SG181553A1 (ko)
TN (1) TN2012000253A1 (ko)
UA (1) UA104933C2 (ko)
WO (1) WO2011072501A1 (ko)
ZA (1) ZA201205217B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
US10071358B2 (en) * 2011-12-08 2018-09-11 Protein Design Lab, Ltd. Antibiotic preparation method and platform system based on same
WO2016023491A1 (en) * 2014-08-12 2016-02-18 The University Of Hong Kong Biophosphonate compounds and gamma delta t cell-mediated therapy for treating epstein-barr virus-associated disorders
CN104604799B (zh) * 2015-02-05 2017-11-21 南华大学 一种鉴定eb病毒对淋巴瘤的诱发性的方法
US20210373004A1 (en) * 2018-11-19 2021-12-02 Bioaster Methods and reagents for multiplex binding experiments
CN111333724B (zh) * 2018-12-19 2022-03-15 中国人民解放军军事科学院军事医学研究院 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-1及其应用
CN111848817B (zh) * 2020-07-28 2021-11-09 中国农业大学 一种兼具抗菌、抗病毒、免疫调节和抗炎活性的多功能杂合肽及其制备方法和应用
CN112125959B (zh) * 2020-10-10 2022-07-29 中山大学肿瘤防治中心 一种抑制eb病毒的肽和编码该肽的dna及其应用
CN113880914B (zh) * 2021-04-25 2023-11-21 内蒙古农业大学 一种抗肿瘤多肽及其衍生物
CN114369158B (zh) * 2021-09-28 2024-04-19 北京亦科信息菌素研究院有限公司 一种抗新冠病毒的信息菌素及其应用
CN113999304B (zh) * 2021-10-13 2023-10-24 北京市农林科学院 抗肠菌素单克隆抗体mAb4及其在肠菌素检测中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1641024A (zh) * 2004-12-10 2005-07-20 四川大学华西医院 抗eb病毒所致肿瘤多肽及其应用与制备方法
US20060193867A1 (en) * 2004-12-10 2006-08-31 West China Hospital, Sichuan Univesity Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
WO2007083175A1 (en) * 2006-01-17 2007-07-26 West China Hospital, Sichuan University Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1164612C (zh) 2001-09-11 2004-09-01 四川新泰克控股有限责任公司 人工组合的抗菌工程多肽及其制备方法
CN101643501B (zh) * 2008-11-07 2012-06-20 畿晋庆三联（北京）生物技术有限公司 一种新型抗生素及其核苷酸序列、制备方法与应用
CN101633699B (zh) * 2009-09-02 2012-02-15 畿晋庆堂国际生物技术有限公司 一种含抗体模拟物的新型抗生素及其制备方法与应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1641024A (zh) * 2004-12-10 2005-07-20 四川大学华西医院 抗eb病毒所致肿瘤多肽及其应用与制备方法
US20060193867A1 (en) * 2004-12-10 2006-08-31 West China Hospital, Sichuan Univesity Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
US20060233813A1 (en) * 2004-12-10 2006-10-19 West China Hospital, Sichuan University Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
WO2007083175A1 (en) * 2006-01-17 2007-07-26 West China Hospital, Sichuan University Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith

Also Published As

Publication number Publication date
CN102101888A (zh) 2011-06-22
AP2012006327A0 (en) 2012-06-30
BR112012017350A2 (pt) 2018-07-24
ZA201205217B (en) 2013-03-27
CO6541633A2 (es) 2012-10-16
MX2012006952A (es) 2012-10-03
IL220296A (en) 2017-07-31
JP5683603B2 (ja) 2015-03-11
HUE033298T2 (en) 2017-11-28
EP2514768B1 (en) 2017-04-05
UA104933C2 (uk) 2014-03-25
MA33921B1 (fr) 2013-01-02
AU2010333588B2 (en) 2013-05-02
NZ600729A (en) 2014-12-24
CL2012001609A1 (es) 2012-12-07
CN102101888B (zh) 2013-03-20
DK2514768T3 (en) 2017-07-17
EP2514768A1 (en) 2012-10-24
KR20120117826A (ko) 2012-10-24
EA030638B1 (ru) 2018-09-28
DOP2012000164A (es) 2012-12-31
US20130066051A1 (en) 2013-03-14
TN2012000253A1 (en) 2013-12-12
CA2784784C (en) 2017-10-03
CU23931B1 (ko) 2013-06-28
EA201270655A1 (ru) 2012-12-28
GEP20156228B (en) 2015-01-26
US8883161B2 (en) 2014-11-11
SG181553A1 (en) 2012-07-30
EP2514768A4 (en) 2013-12-04
JP2013514060A (ja) 2013-04-25
HK1159123A1 (en) 2012-07-27
AU2010333588A1 (en) 2012-06-21
CR20120329A (es) 2012-10-23
IL220296A0 (en) 2012-07-31
WO2011072501A1 (zh) 2011-06-23
CU20120096A7 (es) 2012-07-31
CA2784784A1 (en) 2011-06-23
PE20121722A1 (es) 2012-12-15
KR101464842B1 (ko) 2014-11-27
ES2634944T3 (es) 2017-09-29

Similar Documents

Publication Publication Date Title
AP3535A (en) Fusion polypeptide against eb virus-induced tumor and colicin ia mutant
HK1253887A1 (zh) 因子viii-fc嵌合多肽和雜交多肽及其使用方法
EP2405452A4 (en) ELECTRODE MATERIAL AND ELECTRODE WITH ELECTRODE MATERIAL
ZA201303134B (en) Modified factor ix polypeptides and uses thereof
ZA201200716B (en) Modified factor ix polypeptides and uses thereof
EP2383283A4 (en) NOGGIN PEPTIDE AND ITS USE
GB0916578D0 (en) Polypeptides and uses thereof
IL222382A0 (en) Robo1-fc fusion protein and use thereof for treating tumours
EP2474555A4 (en) PEPTIDE DERIVED FROM WNT10 AND USE THEREOF
EP2496609A4 (en) CHIMERIC RSV-F POLYPEPTIDE AND VLPS ON LENTIVIREN OR ALPHA RETROVIRUS GAG BASE
GB0916576D0 (en) Polypeptides and uses thereof
EP2513137A4 (en) PEPTIDES DERIVED FROM SAPOSINE-A AND USES THEREOF
EP2478014A4 (en) FUSION POLYPEPTIDES AND USES THEREOF
GB0906828D0 (en) Reference electrode and combined electrode
HK1168363A1 (en) Novel peptide and use thereof
GB0818065D0 (en) Immunogenic peptides and uses thereof
IL220146A0 (en) Tmem22 peptides and vaccines including the same
IL215268A0 (en) C6orf167 peptides and vaccines containing the same
EP2408911A4 (en) EXPRESSION OF POLYPEPTIDES IN CILIATES
EP2450374A4 (en) PEPTIDE AND ITS USE
ZA201209021B (en) Therapeutic peptide composition and method
IL222870B (en) The ccl1–ig protein is fused for use in therapy
GB0914019D0 (en) Fusion polypeptide
GB0904177D0 (en) Fusion polypeptide